Literature DB >> 16386986

Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy.

Eisuke Ishizaki1, Shinji Takai, Mari Ueki, Takatoshi Maeno, Midori Maruichi, Tetsuya Sugiyama, Hidehiro Oku, Tsunehiko Ikeda, Mizuo Miyazaki.   

Abstract

PURPOSE: To investigate the involvement of angiotensin-converting enzyme (ACE) with angiogenic factors, vascular endothelial growth factor (VEGF), and matrix metalloproteinase (MMP)-9 in the vitreous of eyes with proliferative diabetic retinopathy (PDR).
DESIGN: Observational case series.
METHODS: Angiotensin-converting enzyme activity in the vitreous was measured by using a synthetic substrate for ACE. VEGF and MMP-9 concentrations were determined by enzyme-linked immunosorbent assay.
RESULTS: Vitreous ACE activity was significantly higher in eyes with PDR (1.4 +/- 1.3 mU/ml) than in eyes with macular holes (0.22 +/- 0.11 mU/ml). Vitreous VEGF concentration in the eyes with PDR (1067 +/- 1076 pg/ml) was significantly higher than in eyes with macular holes (34 +/- 5.5 pg/ml). Vitreous MMP-9 concentration was also significantly higher in eyes with PDR (7.5 +/- 3.8 ng/ml) than in eyes with macular holes (4.2 +/- 1.4 ng/ml). Significant correlations between ACE and VEGF (P < .01) and between ACE and MMP-9 (P < .01) were observed in the vitreous of eyes with PDR.
CONCLUSIONS: Angiotensin-converting enzyme was significantly correlated with angiogenic factors, VEGF and MMP-9, in the vitreous of eyes with PDR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16386986     DOI: 10.1016/j.ajo.2005.08.066

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  23 in total

1.  Genetic variation in the matrix metalloproteinase genes and diabetic nephropathy in type 1 diabetes.

Authors:  Masahiko Kure; Marcus G Pezzolesi; G David Poznik; Pisut Katavetin; Jan Skupien; Jonathon S Dunn; Josyf C Mychaleckyj; James H Warram; Andrzej S Krolewski
Journal:  Mol Genet Metab       Date:  2011-01-14       Impact factor: 4.797

2.  Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy.

Authors:  Ghulam Mohammad; Mohammad Mairaj Siddiquei
Journal:  J Ocul Biol Dis Infor       Date:  2012-07-06

Review 3.  Angiotensin II-related hypertension and eye diseases.

Authors:  Pablo Jesus Marin Garcia; Maria Encarna Marin-Castaño
Journal:  World J Cardiol       Date:  2014-09-26

4.  Validation of molecular and genomic biomarkers of retinal drug efficacy: use of ocular fluid sampling to evaluate VEGF.

Authors:  Rajesh K Sharma; Cheryl L Rowe-Rendleman
Journal:  Neurochem Res       Date:  2010-12-07       Impact factor: 3.996

Review 5.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

6.  Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion.

Authors:  Yukihiko Suzuki; Mitsuru Nakazawa; Kaori Suzuki; Hitoshi Yamazaki; Yasuhiro Miyagawa
Journal:  Jpn J Ophthalmol       Date:  2011-05-03       Impact factor: 2.447

7.  Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.

Authors:  Mervi Holappa; Heikki Vapaatalo; Anu Vaajanen
Journal:  Ann Med       Date:  2020-04-30       Impact factor: 4.709

8.  Renal and retinal effects of enalapril and losartan in type 1 diabetes.

Authors:  Michael Mauer; Bernard Zinman; Robert Gardiner; Samy Suissa; Alan Sinaiko; Trudy Strand; Keith Drummond; Sandra Donnelly; Paul Goodyer; Marie Claire Gubler; Ronald Klein
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

9.  Matrix metalloproteinase-2 dysregulation in type 1 diabetes.

Authors:  Kathryn M Thrailkill; Robert C Bunn; Cynthia S Moreau; Gael E Cockrell; Pippa M Simpson; Hannah N Coleman; J Paul Frindik; Stephen F Kemp; John L Fowlkes
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

10.  Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.

Authors:  Geetanjali Davuluri; Virginia Espina; Emanuel F Petricoin; Mark Ross; Jianghong Deng; Lance A Liotta; Bert M Glaser
Journal:  Arch Ophthalmol       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.